The "word on the street" is that the UK Government and the ABPI, on behalf of the pharmaceutical industry, are close to agreeing a new "voluntary" Pharmaceutical Price Regulation Scheme (PPRS).
Bridgehead International recently completed an independent due diligence study on Tyrell Inc. as part of a fundraising programme.
Richard J Wallace has joined the Bridgehead Board as a Non-Executive Director, following 15 years at GlaxoSmithKline (GSK).
Bridgehead International has announced today the sale of Pharmalicensing Ltd. ("Pharmalicensing"), to UTEK Corporation, an AMEX and LSE-AIM listed company focused on technology transfer.
